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heart rate in a meta-analysis of more than 60,000 patients in 9
large beta-blocker trials (2). Thus, the greater the heart rate
reduction with beta-blockers, the greater the risk of cardiovascular
events in hypertensive patients. The reason that drug-induced
bradycardia is less beneficial than spontaneously occurring brady-
cardia may be related to the dyssynchrony of the reflected pulse
wave and the outgoing pressure wave. Ideally, the reflected wave
should return toward the heart during diastole to augment diastolic
filling. If the wave returns earlier during the cardiac cycle, as is the
case with pharmacologic heart rate slowing, it amplifies the
outgoing pressure wave, thereby increasing systolic pressure. In-
deed, findings from the CAFÉ (Conduit Artery Function Evalu-
ation) (3) study, in which pulse-wave analysis was used to derive
central aortic pressure, documented a pseudo-antihypertensive
effect of the beta-blocker regimen (4). Despite identical brachial
pressure in both treatment arms, central aortic systolic pressure was
lowered significantly less well with atenolol than with amlodipine.
Thus, pulse-wave dyssynchrony, secondary to heart rate slowing,
may account for the beta-blocker–hypertension paradox. This
would indicate that not all heart rate slowing is created equal—
bradycardia induced by negative chronotropic drugs may not
necessarily be as beneficial as bradycardia occurring spontaneously
or being related to aerobic conditioning.
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Reply
Resting heart rate is a strong predictor of cardiovascular and
all-cause mortality in various populations, including hypertensive
patients. Moreover, the strong relationship between heart rate
reduction and mortality reduction has been robustly established by
data on the effect of beta-blockers and, to a lesser extent, heart
rate-reducing calcium-channel blockers in patients after myocar-
dial infarction (MI) and with heart failure (HF) (1).
In their letter to the Journal, Drs. Messerli and Bangalore
suggest that bradycardia induced by negative chronotropic drugs
may not necessarily be as beneficial as bradycardia occurring
physiologically and support the suggestion with the observation
that blood pressure reduction with beta-blockers, which is associ-
ated with heart rate reduction, is less beneficial in minimizing
cardiovascular outcome in hypertensive patients as compared with
other non-heart rate slowing antihypertensive agents.
In contrast with post-MI or HF studies, the beta-blocker
atenolol was the chronotropic drug used in most of the hyperten-
sion clinical trials reported by Drs. Messerli and Bangalore. By
reducing heart rate and myocardial inotropism and increasing left
ventricular (LV) ejection time, atenolol (like the majority of
beta-blockers) alters the pattern of pulse-wave reflection. The
increase in the augmentation index reported after beta-blockers
results in increased central systolic blood pressure in hypertensive
patients. Thus, beta-blockers could have a deleterious effect on
LV-aortic coupling, LV afterload, LV hypertrophy, and, ulti-
mately, the risk of cardiovascular events. The observations could
explain the less-than-expected beneficial effect of atenolol on
clinical outcome in the CAFÉ (Conduit Artery Function Evalu-
ation) study (2) reported by Drs. Messerli and Bangalore.
However, although the pulse-wave dyssynchrony observed with
atenolol may account for the beta-blocker paradox and the increase
in central blood pressure observed in hypertensive patients, we
should be cautious about attributing the phenomenon to heart rate
slowing per se. As previously mentioned, beta-blockers not only
affect heart rate, they also reduce blood pressure and alter cardiac
contractility, relaxation, systolic ejection time, and pulse-wave
reflection.
An interesting point is that for a given reduction in a heart rate,
the dyssynchrony between the forward and the reflected pulse wave
may not be the same for atenolol as for other beta-blockers. (3).
In addition to the potentially deleterious effect of beta-blockers,
as a group, on pulse-wave reflection for reasons unrelated to heart
rate reduction, other issues might be considered in assessing the
impact of beta-blockers, including, perhaps most importantly, the
magnitude of heart rate reduction achieved in the individual trials
or individual patients in the meta-analysis by Bangalore et al. (4),
which may determine the extent to which any deleterious effects of
beta-blockade might be obviated by heart rate slowing.
Therefore, the hypertension paradox observed with beta-
blockers (mainly atenolol) cannot be solely explained by pharma-
cologic heart rate slowing, and findings should not be extrapolated
to pharmacologic interventions aiming at pure heart rate reduction.
In other words, the way in which one slows the heart rate may be
important in determining the outcome of heart rate slowing. We
all are aware, however, of the limitations of observational datasets,
whether when suggesting benefit of a spontaneously “low” heart
rate or possible harm from pharmacologic heart rate reduction with
beta-blockers in hypertension. Fortunately, the hypothesis that
heart rate lowering is beneficial clinically is being put to test in 2
large-scale outcome randomized clinical trials.
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